Jan Willem C. Gratama

Jan Willem C. Gratama

Auto-generated profile, based on publicly available information

Jan Willem C. Gratama

Department of Radiology and Nuclear Medicine, Gelre Ziekenhuizen, Apeldoorn, The Netherlands

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
CACarlijn M van der Aalst
Carlijn M van der Aalst
SDSabine J A M Denissen
Sabine J A M Denissen
MVMarleen Vonder
Marleen Vonder
JGJan Willem C Gratama
Jan Willem C Gratama
HAHenk J Adriaansen
Henk J Adriaansen
HKHarry J de Koning
Harry J de Koning
Aims: Screening for a high cardiovascular disease (CVD) risk followed by preventive treatment can potentially reduce coronary heart disease-related morbidity and mortality. ROBINSCA (Risk Or Benefit IN Screening for CArdiovascular disease) is a population-based randomized controlled screening trial that investigates the effectiveness of CVD screening in asymptomatic participants using the Systematic COronary Risk Evaluation (SCORE) model or coronary artery calcium (CAC) scoring. This study describes the distributions in risk and treatment in the ROBINSCA trial. Methods and results: Individuals at expected elevated CVD risk were randomized into screening arm A (n = 14 478; SCORE, 10-year fatal and non-fatal risk); or screening arm B (n = 14 450; CAC scoring). Preventive treatment was largely advised according to current Dutch guidelines. Risk and treatment differences between the screening arms were analysed. A total of 12 185 participants (84.2%) in arm A and 12 950 (89.6%) in arm B were screened. In total, 48.7% were women, and median age was 62 (interquartile range 10) years. SCORE screening identified 45.1% at low risk (SCORE < 10%), 26.5% at intermediate risk (SCORE 10–20%), and 28.4% at high risk (SCORE ≥ 20%). According to CAC screening, 76.0% were at low risk (Agatston < 100), 15.1% at high risk (Agatston 100–399), and 8.9% at very high risk (Agatston ≥ 400). CAC scoring significantly reduced the number of individuals indicated for preventive treatment compared to SCORE (relative reduction women: 37.2%; men: 28.8%). Conclusion: We showed that compared to risk stratification based on SCORE, CAC scoring classified significantly fewer men and women at increased risk, and less preventive treatment was indicated. Trial registration number: NTR6471.

1 January 2018 in Academic Radiology
Verified
Journal Article
Closed access
MVMarleen Vonder
Marleen Vonder
CACarlijn M. van der Aalst
Carlijn M. van der Aalst
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
POPeter van Ooijen
Peter van Ooijen
DKDirkjan Kuijpers
Dirkjan Kuijpers
MOMatthijs Oudkerk
Matthijs Oudkerk

30 January 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
JMJames L. Mulshine
James L. Mulshine
BPBruce Pyenson
Bruce Pyenson
CHCheryl Healton
Cheryl Healton
CACarolyn Aldige
Carolyn Aldige
RARiccardo S. Avila
Riccardo S. Avila
MOMatthijs Oudkerk
Matthijs Oudkerk

28 December 2024 in European Journal of Cancer
Verified
Journal Article
Open access
AWAnna N.H. Walstra
Anna N.H. Walstra
HLHarriet Louise Lancaster
Harriet Louise Lancaster
MHMarjolein A. Heuvelmans
Marjolein A. Heuvelmans
CACarlijn M. van der Aalst
Carlijn M. van der Aalst
JHJuul Hubert
Juul Hubert
MOMatthijs Oudkerk
Matthijs Oudkerk
Lung cancer screening (LCS) with low-dose CT (LDCT) reduces lung-cancer-related mortality in high-risk individuals. AI can potentially reduce radiologist workload as first-read-filter by ruling-out negative cases. The feasibility of AI as first reader was evaluated in the European 4-IN-THE-LUNG-RUN (4ITLR) trial, comparing its negative-misclassifications (NMs) to those of radiologists and the impact on referral rates. NMs were collected from 3678 baseline LDCTs of the 4ITLR-dataset. LDCTs were read independently by radiologists and dedicated AI software (AVIEW-LCS, v1.1.42.92, Coreline-Soft, Seoul, Korea). A case was designated as NM when nodules > 100 mm3 were present and either radiologist or AI gave a negative-classification (only nodules 300 mm3) classification, warranting referral for clinical-workup. Overall, there were 102 referrals (2.8 %) at baseline. Of the 3678 baseline scans, 438 NMs (11.9 %) were identified (age individuals: 68 (IQR: 64-73) years, 241 men); 31 (0.8 %) by AI and 407 (11.1 %) by radiologists. Among the 31 AI-NMs, 3 were classified positive and 28 indeterminate. Among the 407 radiologist-NMs, 4 were classified positive, and 403 were indeterminate, of which 8 were classified positive after receiving a three-month follow-up CT. Radiologists, as first reader, would have led to 12/102 (11.8 %) missed referrals, higher than the 3/102 (2.9 %) of AI. This study showed AI outperforms radiologists with significantly less NMs and therefore shows promise as first reader in a LCS program at baseline, by independently ruling-out negative cases without substantially increasing the risk of missed clinical referrals.

25 February 2025 in European Journal of Cancer
Verified
Journal Article
Open access
HLHarriet Louise Lancaster
Harriet Louise Lancaster
BJBeibei Jiang
Beibei Jiang
MDMichael P.A. Davies
Michael P.A. Davies
JGJan Willem C. Gratama
Jan Willem C. Gratama
MSMario Silva
Mario Silva
MOMatthijs Oudkerk
Matthijs Oudkerk
Artificial intelligence (AI) could reduce lung cancer screening computer tomography (CT)-reading workload if used as a first-reader, ruling-out negative CT-scans at baseline. Evidence is lacking to support AI performance when compared to gold-standard lung cancer outcomes. This study validated the performance of a commercially available AI software in the UK lung cancer screening (UKLS) trial dataset, with comparison to human reads and histological lung cancer outcomes, and estimated CT-reading workload reduction. 1252 UKLS-baseline-CT-scans were evaluated independently by AI and human readers. AI performance was evaluated on two-levels. Firstly, AI classification and individual reads were compared to a EU reference standard (based on NELSON2.0-European Position Statement) determined by a European expert panel blinded from individual results. A positive misclassification was defined as a nodule positive read ≥ 100mm3 and no/<100mm3 nodules in the expert read; A negative misclassification was defined as a nodule negative read, whereas an indeterminate or positive finding in the expert read. Secondly, AI nodule classification was compared to gold-standard histological lung cancer outcomes. CT-reading workload reduction was calculated from AI negative CT-scans when AI was used as first-reader. Expert panel reference standard reported 815 (65 %) negative and 437 (35 %) indeterminate/positive CT-scans in the dataset of 1252 UKLS-participants. Compared to the reference standard, AI resulted in less misclassification than human reads, NPV 92·0 %(90·2 %-95·3 %). On comparison to gold-standard, AI detected all 31 baseline-round lung cancers, but classified one as negative due to the 100mm3 threshold, NPV 99·8 %(99·0 %-99·9 %). Estimated maximum CT-reading workload reduction was 79 %. Implementing AI as first-reader to rule-out negative CT-scans, shows considerable potential to reduce CT-reading workload and does not lead to missed lung cancers.

8 September 2013 in European Radiology
Verified
Journal Article
Closed access
PDF file
OGon behalf of the OPTIMAP study group
on behalf of the OPTIMAP study group
MLMarjolein M. N. Leeuwenburgh
Marjolein M. N. Leeuwenburgh
SJSebastiaan Jensch
Sebastiaan Jensch
JGJan W. C. Gratama
Jan W. C. Gratama
ASAart Spilt
Aart Spilt
JSJaap Stoker
Jaap Stoker